GlassScriptPhysician profile
Sanjeev Puri
NPI 1730420399
$2,007.05
in general payments reported to CMS, 2019-2025
33 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.06 · 2020: $166 · 2021: $267 · 2022: $356 · 2023: $500 · 2024: $337 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $332.07 | 2020-2025 | Wegovy |
| Amgen INC. | $195.33 | 2023-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $154.65 | 2023-2024 | |
| Integra Lifesciences Corporation | $122.12 | 2022 | |
| Glaxosmithkline, LLC. | $115.82 | 2022-2025 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $99.67 | 2022-2025 | Gvoke Hypopen |
| Lilly USA, LLC | $98.03 | 2024-2025 | Zepbound, Mounjaro |
| Alkermes, INC. | $94.47 | 2020-2024 | Vivitrol, Vivitrol |
| Stryker Corporation | $92.40 | 2023-2025 | Medpor, Vsp System, Vsp Cranial |
| Neurocrine Biosciences, INC. | $67.80 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $61.46 | 2020-2021 | |
| Corcept Therapeutics | $52.80 | 2024-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $49.31 | 2022-2023 | Farxiga |
| Sunovion Pharmaceuticals INC. | $41.94 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.91 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $34.08 | 2024 | |
| Edwards Lifesciences Corporation | $32.86 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Pfizer INC. | $32.60 | 2022-2023 | |
| Tactile Systems Technology INC | $28.59 | 2023 | Flexitouch Plus, Entre Plus |
| Mannkind Corporation | $28.47 | 2020-2022 | |
| Qiagen, LLC | $28.20 | 2022 | |
| Averitas Pharma INC. | $25.93 | 2025 | Qutenza |
| Acell, INC. | $22.06 | 2019 | |
| Lundbeck LLC | $18.25 | 2020 | |
| Solventum Corporation | $17.97 | 2024 | Activ.A.C. |
| Dexcom, INC. | $16.67 | 2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $16.63 | 2023 | Cologuard Collection Kit |
| Lucid Diagnostics INC. | $16.48 | 2022 | |
| Antares Pharma, INC. | $15.97 | 2023 | Xyosted, Tlando, Nocdurna |
| Redhill Biopharma INC. | $14.88 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.64 | 2024 | Rexulti |
| Astellas Pharma US INC | $14.11 | 2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Puri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.